All Updates

All Updates

icon
Filter
FDA approval
Labcorp receives USD FDA De Novo authorization for PGDx Elio Plasma Focus Dx launch
Precision Medicine
Aug 2, 2024
This week:
Partnerships
T-Mobile partners with OpenAI to develop AI-powered customer service platform
Generative AI Applications
Today
Partnerships
Runway partners with Lionsgate to develop AI video tools using studio's movie catalog
Generative AI Applications
Yesterday
Funding
QMill raises EUR 4 million in seed funding to provide quantum computing industrial applications
Quantum Computing
Yesterday
Product updates
QuiX Quantum launches 'Bia' quantum cloud computing service for quantum solutions
Quantum Computing
Yesterday
Partnerships
Oxford Ionics and Infineon Technologies partner to build portable quantum computer for Cyberagentur
Quantum Computing
Yesterday
Partnerships
Product updates
Tencent Ai Lab launches EzAudio AI for text-to-audio generation with Johns Hopkins University
Foundation Models
Yesterday
Funding
TON secures USD 30 million in investment from Bitget and Foresight Ventures
Web3 Ecosystem
Yesterday
Funding
Hemi Labs raises USD 15 million in funding to launch blockchain network
Web3 Ecosystem
Yesterday
Product updates
Fivetran launches Hybrid Deployment for data pipeline management
Machine Learning Infrastructure
Yesterday
Product updates
Fivetran launches Hybrid Deployment for data pipeline management
Data Infrastructure & Analytics
Yesterday
Precision Medicine

Precision Medicine

Aug 2, 2024

Labcorp receives USD FDA De Novo authorization for PGDx Elio Plasma Focus Dx launch

FDA approval

  • Labcorp has received US FDA De Novo marketing approval for PGDx elio plasma focus Dx, which is claimed to be the first and only test kit in the industry for pan-solid tumor liquid biopsy. The pricing details were not disclosed.

  • PGDx elio plasma focus Dx uses next-generation sequencing to detect single nucleotide variants (SNVs), insertions, and deletions (indels) in 33 genes, copy number amplifications (CNAs) in five genes, and translocations in three genes. The test uses high-throughput hybridization-based capture technology and is complemented by automated bioinformatics for quick results.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.